

**Amendments to the Claims:**

This claim listing will replace all prior versions and listings of claims in the application:

**Claim Listing:**

1. (Previously Presented) A synthetic oligonucleotide selected from the group consisting of SEQ ID NOS:7-19 and 45, which oligonucleotide inhibits HBV replication.
- 2-7 (Canceled)
8. (Currently Amended) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 7 or 58.
9. (Currently Amended) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 8 or 59.
10. (Currently Amended) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 9, 60, or 61.
11. (Original) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 10.
12. (Original) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 11.
13. (Original) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 12.
14. (Original) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 13.
15. (Original) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 14.
16. (Currently Amended) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 15, 62, or 63.
17. (Currently Amended) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 16 or 64.

18. (Original) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 17.
19. (Original) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 18.
20. (Currently Amended) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 19 or 65.
- 21-35 (Canceled)
36. (Previously Presented) The synthetic oligonucleotide of claim 1, wherein the oligonucleotide is SEQ ID NO:45.
- 37-39 (Canceled)
40. (Original) The synthetic oligonucleotide of claim 1 which is modified.
41. (Original) The oligonucleotide of claim 40 wherein the modification comprises at least one internucleotide linkage selected from the group consisting of alkylphosphonate, phosphorothioate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and combinations thereof.
42. (Original) The oligonucleotide of claim 41 comprising at least one phosphorothioate internucleotide linkage.
43. (Original) The oligonucleotide of claim 42 comprising one phosphorothioate internucleotide linkage.
44. (Original) The oligonucleotide of claim 1 which comprises at least one deoxyribonucleotide.
45. (Original) The oligonucleotide of claim 1 which comprises at least one ribonucleotide.
46. (Original) The oligonucleotide of claim 44 which comprises at least one ribonucleotide.

- 47. (Original) The oligonucleotide of claim 45 comprising at least one 2'-O-methyl nucleotide.
- 48. (Original) A kit comprising at least one oligonucleotide of claim 1.
- 49. (Original) A kit comprising at least two oligonucleotides of claim 1.
- 50. (Previously Presented) A composition comprising at least one oligonucleotide of claim 1 admixed with a pharmaceutically acceptable carrier.

51-206 (Canceled)

- 207. (Previously Presented) The synthetic oligonucleotide of claim 16 which is modified.
- 208. (Previously Presented) The oligonucleotide of claim 207 wherein the modification comprises at least one internucleotide linkage selected from the group consisting of alkylphosphonate, phosphorothioate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and combinations thereof.
- 209. (Previously Presented) The oligonucleotide of claim 208 comprising at least one phosphorothioate internucleotide linkage.
- 210. (Previously Presented) The oligonucleotide of claim 209 comprising one phosphorothioate internucleotide linkage.
- 211. (Previously Presented) The oligonucleotide of claim 17 which comprises at least one deoxyribonucleotide.
- 212. (Previously Presented) The oligonucleotide of claim 17 which comprises at least one ribonucleotide.
- 213. (Previously Presented) The oligonucleotide of claim 211 which comprises at least one ribonucleotide.

214. (Previously Presented) The oligonucleotide of claim 212 comprising at least one 2'-O-methyl nucleotide.
215. (Previously Presented) A kit comprising at least the oligonucleotide of claim 16.
216. (Previously Presented) The synthetic oligonucleotide of claim 19 which is modified.
217. (Previously Presented) The oligonucleotide of claim 216 wherein the modification comprises at least one internucleotide linkage selected from the group consisting of alkylphosphonate, phosphorothioate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and combinations thereof.
218. (Previously Presented) The oligonucleotide of claim 217 comprising at least one phosphorothioate internucleotide linkage.
219. (Previously Presented) The oligonucleotide of claim 216 comprising phosphorothioate internucleotide linkages.
220. (Previously Presented) The oligonucleotide of claim 219 which comprises at least one deoxyribonucleotide.
221. (Previously Presented) The oligonucleotide of claim 220 which comprises at least one ribonucleotide.
222. (Previously Presented) The oligonucleotide of claim 19 which comprises at least one ribonucleotide.